Press Releases

VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne

July, 19 2021

BRIDGEWATER, N.J., July 19, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the initiation of an investigator initiated trial (“IIT” or “study”) evaluating the safety and efficacy of AMZEEQ® (minocycline) topical foam, 4%, as a companion treatment with oral isotretinoin in patients with moderate to severe acne. The study is supported by VYNE and is being conducted by the Austin Institute for Clinical Research in Texas. “Isotretinoin has been widely used for the management of severe or scarring acne since its introduction as Accutane® in the 1980s. However, its teratogenic properties means that patients…

Read More

VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digital Event

June, 29 2021

BRIDGEWATER, N.J., June 29, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that Dr. Iain Stuart, Chief Scientific Officer, will participate in and moderate a scientific panel discussion at the 2nd Annual JAK Inhibitors Drug Development Digital Event, to take place virtually June 29-July 1, 2021. Event Details: Day:   Wednesday, June 30, 2021 Time:  2:40pm Eastern Time Panel:  Past, Present & Future Combinational Opportunities with JAKi Topics to be addressed on the panel include the current dearth of JAK inhibitors in certain disease profiles and speculation on the use of combinational approaches and…

Read More

VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

May, 06 2021

BRIDGEWATER, N.J., May 06, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update. “Our sales organization continues to drive utilization of AMZEEQ and ZILXI, with prescriptions for both products gaining momentum,” said David Domzalski, Chief Executive Officer of VYNE Therapeutics. “During the first quarter, we unveiled our newest candidate FMX114, a combination topical gel product candidate for the treatment of mild-to-moderate atopic dermatitis. We plan to take FMX114 into a Phase 2a study in the third quarter, with top-line…

Read More

VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021

April, 28 2021

BRIDGEWATER, N.J., April 28, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the first quarter ended March 31, 2021, on Thursday, May 6, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details: Thursday, May 6th @ 8:30am Eastern Time Toll Free:  800-909-4985 International: 312-281-1211 Conference ID: 21993618 Webcast: http://public.viavid.com/index.php?id=144542 A replay of the call will be archived on the Company’s website at www.vynetherapeutics.com…

Read More

VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021

April, 28 2021

BRIDGEWATER, N.J., April 28, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the first quarter ended March 31, 2021, on Thursday, May 6, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Read More

VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences

March, 04 2021

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference. Presentation details can be found below. Barclays Global Healthcare Conference Day: Tuesday, March 9, 2021 Time: 8:00am Eastern Time Format: Fireside chat Webcast Link: https://kvgo.com/2021-global-healthcare-conference/vyne-therapeutics-2021     H.C. Wainwright Global Life Sciences Conference Day & Time: On demand, beginning 7:00am Eastern Time, Tuesday, March 9, 2021 Format: Fireside chat Webcast Link: https://journey.ct.events/view/7534c623-91e5-4fa6-9d64-6dbed8781b9a About VYNE Therapeutics Inc.VYNE’s mission is…

Read More